BioNTech SE (22UA.DE)
Develops mRNA vaccines and cancer treatments to train the immune system to fight disease.
80.70+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-12.3%
The outlook
BioNTech is trading near the lower third of its 52-week range at €80.70. The stock sits mixed relative to its moving averages, suggesting no clear directional momentum. Analyst coverage leans neutral overall, with sentiment neither notably bullish nor bearish at present.
What’s behind the score
Price trendMixed vs its moving averages
52-week range33% of the way from its 52-week low to high
Market cap
$20.41B
52-wk high
105.70
52-wk low
68.30
50-day avg
79.51
200-day avg
84.32
Trailing P/E
—